Predictors of No-Reflow Phenomenon in Primary Percutaneous Coronary Intervention among Patients with Acute Myocardial Infarction
DOI:
https://doi.org/10.61919/jhrr.v4i1.423Keywords:
No-reflow phenomenon, Acute myocardial infarction, primary percutaneous coronary intervention, predictors, systolic blood pressure, diabetes, hypertension, cardiovascular diseaseAbstract
Background: The no-reflow phenomenon, characterized by the failure to restore myocardial blood flow after reopening an occluded artery in acute myocardial infarction (AMI) patients undergoing primary percutaneous coronary intervention (PCI), has significant implications for patient prognosis. Understanding the predictors of no-reflow is crucial for improving clinical outcomes in this high-risk population.
Objective: This study aims to identify the predictors of the no-reflow phenomenon in patients with AMI undergoing PCI and to assess their impact on the efficacy of the intervention.
Methods: Conducted at Lady Reading Hospital's Cardiology Department, this descriptive study retrospectively analyzed 120 AMI patients treated with PCI from May 2023 to November 2023. Ethical approval was obtained, and the study conformed to the Declaration of Helsinki. The diagnosis of AMI was based on clinical symptoms and electrocardiographic findings. Experienced cardiologists performed PCI, and no-reflow was defined using Thrombolysis in Myocardial Infarction (TIMI) flow grades and Myocardial Blush Grade (MBG). Data were analyzed using SPSS Version 25, focusing on demographic variables, clinical presentations, and procedural details to identify predictors of no-reflow.
Results: Out of 120 patients, 70.8% were male. The incidence of no-reflow was 22.5%. Significant predictors of no-reflow included systolic blood pressure < 100 mmHg (51.9% in no-reflow vs. 28.0% in normal flow, P=0.02), diabetes (59.3% vs. 34.4%, P=0.02), hypertension (77.8% vs. 31.2%, P=0.0001), and history of cardiovascular disease (11.1% vs. 2.2%, P=0.04).
Conclusion: The study identified diabetes, hypertension, low systolic blood pressure, and a history of cardiovascular disease as significant predictors of the no-reflow phenomenon in AMI patients undergoing PCI. These findings highlight the importance of identifying and managing these risk factors to enhance the success of PCI and improve patient outcomes.
Downloads
References
Moore A, Goerne H, Rajiah P, Tanabe Y, Saboo S, Abbara S. Acute myocardial infarct. Radiologic Clinics. 2019;57(1):45-55.
Ramathebane M, Maja L, Sello M. Exploring cardiovascular diseases treatment in Africa. LIFESTYLE and epidemiology: the double burden of poverty and cardiovascular diseases in African populations. 2021;6:299.
Bhatt DL. Percutaneous coronary intervention in 2018. JAMA. 2018;319(20):2127-8.
Kloner RA, King KS, Harrington MG. No-reflow phenomenon in the heart and brain. American Journal of Physiology-Heart and Circulatory Physiology. 2018;315(3):550-62.
Fajar JK, Heriansyah T, Rohman MS. The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis. Indian Heart Journal. 2018;70:406-18.
Kaur G, Baghdasaryan P, Natarajan B, Sethi P, Mukherjee A, Varadarajan P. Pathophysiology, diagnosis, and management of coronary no-reflow phenomenon. International Journal of Angiology. 2021;30(1):15-21.
Kumar J, O’Connor CT, Kumar R, Arnous SK, Kiernan TJ. Coronary no-reflow in the modern era: a review of advances in diagnostic techniques and contemporary management. Expert Review of Cardiovascular Therapy. 2019;17(8):605-23.
Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the "no reflow" phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996;93(2):223-228.
Oikonomou E, Mourouzis K, Vogiatzi G, Siasos G, Deftereos S, Papaioannou S, et al. Coronary microcirculation and the no-reflow phenomenon. Current pharmaceutical design. 2018;24(25):2934-42.
Kloner RA. The importance of no-reflow/microvascular obstruction in the STEMI patient. European heart journal. 2017;38(47):3511-3.
Galasso G, Schiekofer S, D’Anna C, Gioia GD, Piccolo R, Niglio T, et al. No-reflow phenomenon: pathophysiology, diagnosis, prevention, and treatment. A review of the current literature and future perspectives. Angiology. 2014;65(3):180-9.
Ge L, Zhou X, Ji WJ, Lu RY, Zhang Y, Zhang YD, et al. Neutrophil extracellular traps in ischemia-reperfusion injury-induced myocardial no-reflow: therapeutic potential of DNase-based reperfusion strategy. American Journal of Physiology-Heart and Circulatory Physiology. 2015 Mar 1;308(5):500-9.
Liu WB, Zou ZP, Jiang HP, Li Q, Guo FM, Wang Z, et al. Clinical significance of dynamic changes in hs-CRP and ADAMTS13 levels in the blood serum of patients with no-reflow after PCI operation. European Review for Medical & Pharmacological Sciences. 2016;20(19):35-41.
Börekçi A, Gür M, Türkoğlu C, Baykan AO, Şeker T, Şahin DY, et al. Neutrophil to lymphocyte ratio predicts left ventricular remodeling in patients with ST elevation myocardial infarction after primary percutaneous coronary intervention. Korean circulation journal. 2016;46(1):15-22.
Harrison R.W., Aggarwal A., Ou F.S., Klein L.W., Rumsfeld J.S., Roe M.T. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am. J. Cardiol. 2013;111(2):178–184.
Rezkalla S.H., Stankowski R.V., Hanna J., Kloner R.A. Management of no-Reflow Phenomenon in the catheterization laboratory. JACC Cardiovasc Interv. 2017;10(3):215–223.
Niccoli G., Burzotta F., Galiuto L., Crea F. Myocardial no-reflow in humans. J. Am. Coll. Cardiol. 2009;54(4):281–292.
Mazhar J., Mashicharan M., Farshid A. Predictors and outcome of no-reflow post primary percutaneous coronary intervention for ST elevation myocardial infarction. Int J Cardiol Heart Vasc. 2015;10:8–12.
Mahmoud AH, Taha NM, Baraka K, Ashraf M, Shehata S. Clinical and procedural predictors of suboptimal myocardial reperfusion in primary percutaneous coronary intervention. Int J Cardiol Heart Vasc. 2019;23:100357.
Del Turco S., Basta G., De Caterina A.R., Sbrana S., Paradossi U., Taddei A. ,et al. Different inflammatory profile in young and elderly STEMI patients undergoing primary percutaneous coronary intervention (PPCI): its influence on no-reflow and mortality. Int. J. Cardiol. 2019;290:34–39.
Kaya A., Keskin M., Tatlisu M.A., Uzman O., Borklu E., Cinier G., et al. Atrial fibrillation: a novel risk factor for no-reflow following primary percutaneous coronary intervention. Angiology. 2019:3319719840589.
Shakiba M, Salari A, Mirbolouk F, Sotudeh N, Nikfarjam S. Clinical, Laboratory, and Procedural Predictors of No-Reflow in Patients Undergoing Primary Percutaneous Coronary Intervention. J Tehran Heart Cent. 2020;15(2):50-56.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Sadam Hussain, Tariq Nawaz, Wasim Sajjad, Muhammad Amin, Hassan Ali
This work is licensed under a Creative Commons Attribution 4.0 International License.
